Iterum Therapeutics plc
ITRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2 | $2 | $2 |
| Gross Profit | -$0 | -$2 | -$2 | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $38 | $16 | $9 |
| G&A Expenses | $8 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $7 | $13 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18 | $46 | $29 | $22 |
| Operating Income | -$19 | -$47 | -$30 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$6 | $10 | -$14 | -$66 |
| Pre-Tax Income | -$25 | -$38 | -$44 | -$91 |
| Tax Expense | $0 | $1 | $0 | $1 |
| Net Income | -$25 | -$38 | -$44 | -$92 |
| % Margin | – | – | – | – |
| EPS | -1.26 | -2.96 | -3.63 | -8.41 |
| % Growth | 57.4% | 18.5% | 56.8% | – |
| EPS Diluted | -1.26 | -2.96 | -3.63 | -8.41 |
| Weighted Avg Shares Out | 20 | 13 | 12 | 11 |
| Weighted Avg Shares Out Dil | 20 | 13 | 12 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $6 |
| Depreciation & Amortization | $0 | $2 | $2 | $2 |
| EBITDA | -$22 | -$35 | -$40 | -$83 |
| % Margin | – | – | – | – |